Literature DB >> 25263272

Current issues in inflammatory bowel disease neoplasia.

Michael Vieth1, Helmut Neumann.   

Abstract

Recent histological criteria and developments in the field of endoscopic imaging have led to higher detection rates of neoplasms in ulcerative colitis. Once a lesion is detected, endoscopic resection is recommended to guide subsequent surveillance or therapy and to gain adequate material for histological diagnosis. Further management is based on the grade of neoplasia and on whether the neoplasia is categorized as sporadic or colitis-associated. Nevertheless it may sometimes be difficult to distinguish colitis-associated neoplasms from sporadic neoplasms. A better way to report this may be ultimately classified. Here, we review endoscopic and histological parameters to help to differentiate colitis-associated neoplasia from sporadic lesions and discuss pathogenesis and therapeutic options.
© 2015 John Wiley & Sons Ltd.

Entities:  

Keywords:  adenoma-like lesion or mass; advanced endoscopic imaging; carcinogenesis; dysplasia-associated lesion or mass; endocytoscopy; endomicroscopy; histology; neoplasia; raised lesion with dysplasia; ulcerative colitis

Mesh:

Year:  2015        PMID: 25263272     DOI: 10.1111/his.12565

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  3 in total

Review 1.  Role of high-mobility group box 1 protein in inflammatory bowel disease.

Authors:  Zhen Hu; Xiaoyun Wang; Lei Gong; Gaojue Wu; Xiaobin Peng; Xuejun Tang
Journal:  Inflamm Res       Date:  2015-06-16       Impact factor: 4.575

2.  A subepithelial lesion in a patient with long-standing ulcerative colitis.

Authors:  Suhyun Park; Jihun Kim; Dong-Hoon Yang
Journal:  Clin Endosc       Date:  2022-09-19

Review 3.  Five-aminosalicylic Acid: an update for the reappraisal of an old drug.

Authors:  Cristiana Perrotta; Paolo Pellegrino; Eliana Moroni; Clara De Palma; Davide Cervia; Piergiorgio Danelli; Emilio Clementi
Journal:  Gastroenterol Res Pract       Date:  2015-01-21       Impact factor: 2.260

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.